Brief: Vir Biotechnology Q4 Cash & Investments USD 1,100 Million
26/02/2025 21:05
Feb 26 (Reuters) - Vir Biotechnology Q4 revenue USD 12.4 million vs. IBES estimate USD 8.14 million.
Recent news on Vir Biotechnology
See all newsVir, Gilead team up on solid tumor cancer therapies in up to $1.9 billion deal
Vir Biotechnology gains after up to $1.9 billion licensing deal with Gilead
Brief: Vir Biotechnology Announces Psma-Targeted Pro-Xten® Dual-Masked T-Cell Engager Vir-5500 Received FDA Fast Track Designation For The Treatment Of Prostate Cancer
Brief: Vir Biotechnology Appoints David Liu As Chief Medical Officer
Vir Biotechnology rises after naming Theravance's Sawaf as CFO